




Fig. 1




Fig. 2




Fig 3

Fig. 4




Fig. 5





Fig. 6



Patient Disposition




Fig. 11

Patient Disposition




Fig. 12

Fig. 13 IGA Score Category Shift From Baseline to Week 12 (ITT Population)

Treatment Group	Baseline Reference Range	Post-baseline Reference Range					Total n (%)
		IGA-0 (%)	IGA-1 (%)	IGA-2 (%)	IGA-3 (%)	IGA-4 (%)	
Placebo N=52	IGA-3	0 (0.0)	0 (0.0)	4 (7.7)	29 (55.8)	8 (15.4)	41 (78.8)
	IGA-4	0 (0.0)	0 (0.0)	0 (0.0)	3 (5.8)	8 (15.4)	11 (21.2)
	Total	0 (0.0)	0 (0.0)	4 (7.7)	32 (61.5)	16 (30.8)	52 (100.0)
Secukinumab N=53	IGA-3	12 (23.1)	20 (38.5)	5 (9.6)	0 (0.0)	0 (0.0)	37 (71.2)
	IGA-4	3 (5.8)	6 (11.5)	3 (5.8)	3 (5.8)	0 (0.0)	15 (28.8)
	Total	15 (28.8)	26 (50.0)	8 (15.4)	3 (5.8)	0 (0.0)	52 (100.0)
30 mg (x4), Q4 N=52	IGA-3	8 (15.4)	15 (28.8)	14 (26.9)	1 (1.9)	0 (0.0)	38 (73.1)
	IGA-4	1 (1.9)	1 (1.9)	5 (9.6)	6 (11.5)	1 (1.9)	14 (26.9)
	Total	9 (17.3)	16 (30.8)	19 (36.5)	7 (13.5)	1 (1.9)	52 (100.0)
60 mg (x4), Q4 N=52	IGA-3	11 (21.2)	25 (48.1)	1 (1.9)	0 (0.0)	0 (0.0)	37 (71.2)
	IGA-4	2 (3.8)	7 (13.5)	5 (9.6)	1 (1.9)	0 (0.0)	15 (28.8)
	Total	13 (25.0)	32 (61.5)	6 (11.5)	1 (1.9)	0 (0.0)	52 (100.0)
120 mg (x4), Q8 N=53	IGA-3	17 (32.1)	15 (28.3)	7 (13.2)	0 (0.0)	0 (0.0)	39 (73.6)
	IGA-4	3 (5.7)	6 (11.3)	2 (3.8)	3 (5.7)	0 (0.0)	14 (26.4)
	Total	20 (37.7)	21 (39.6)	9 (17.0)	3 (5.7)	0 (0.0)	53 (100.0)
120 mg (x6), Q4 N=51	IGA-3	13 (25.5)	21 (41.2)	5 (9.8)	0 (0.0)	1 (2.0)	40 (78.4)
	IGA-4	5 (9.8)	6 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)	11 (21.6)
	Total	18 (35.3)	27 (52.9)	5 (9.8)	0 (0.0)	1 (2.0)	51 (100.0)

IGA=investigator’s global assessment; ITT=intent-to-treat; LOCF=last observation carried forward.
Baseline is the last measurement prior to the first dose of any study treatment

Fig. 14 DLQI 0/1 Response Rates (NRI) at Week 12 and 24 (ITT Population)

Time point		Placebo/120 mg normal load, Q4 n=52	Secukinumab n=53	30 mg normal load, Q4 n=52	60 mg normal load, Q4 n=52	120 mg normal load, Q8 after wk 12 n=53	120 mg augmented load, Q4 n=51
Week 12	DLQI response (NRI), n/N(%) ^a	1/52 (1.9)	32/53 (60.4)	24/52 (46.2)	39/52 (75.0)	35/53 (66.0)	33/51 (64.7)
	95% CI (exact) ^b	(0.0, 10.3)	(46.0, 73.5)	(32.2, 60.5)	(61.1, 86.0)	(50.1, 78.5)	(50.1, 77.6)
Week 24	DLQI response (NRI), n/N(%) ^a	33/52 (63.5)	33/53 (62.3)	32/52 (61.5)	43/52 (82.7)	39/53 (73.6)	33/51 (64.7)
	95% CI (exact) ^b	33/51 (64.7)	(47.9, 75.2)	(47.0, 74.7)	(69.7, 91.8)	(59.7, 84.7)	(50.1, 77.6)

CI=confidence interval; DLQI=Dermatology Life Quality Index; ITT=intent-to-treat; NRI=non-responder imputation; Q4=every 4 weeks; Q8=every 8 weeks.
^aPercentage of response imputed with NRI is calculated by n/N*100%.
^b95% exact CI using the Clopper-Pearson method.

